NASDAQ:SRNE - Sorrento Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$7.25 +0.05 (+0.69 %)
(As of 05/23/2018 09:13 AM ET)
Previous Close$7.20
Today's Range$7.05 - $7.35
52-Week Range$1.50 - $10.65
Volume1.06 million shs
Average Volume1.79 million shs
Market Capitalization$668.34 million
P/E RatioN/A
Dividend YieldN/A
Beta2.4

About Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics logoSorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company is focusing on the development of chimeric antigen receptor (CAR)-based immunotherapies using autologous T-cells. It is developing CD38 Directed CAR-T, a cellular therapy used for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; CD123 Directed CAR-T for the treatment of acute myelogenous leukemia; and human antibodies, including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT, and CD137. The company is also developing intracellular targeting antibodies comprising STAT3, Mutant KRAS, MYC, p53, and TAU to modulate the evolution of cancer, inflammation, autoimmune diseases, diabetes, central nervous system diseases, cardiovascular diseases, and viral infections; and oncolytic viruses that infect and selectively multiply in and destroy tumor cells without damaging healthy tissue. In addition, it offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. The company has a licensing agreement with Mabtech Limited to develop and commercialize multiple prespecified biosimilar and biobetter antibodies from based on Erbitux, Remicade, Xolair, and Simulect. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.

Receive SRNE News and Ratings via Email

Sign-up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SRNE
CUSIPN/A
Phone858-203-4100

Debt

Debt-to-Equity Ratio0.02
Current Ratio0.71
Quick Ratio0.71

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$151.85 million
Price / Sales4.43
Cash Flow$0.2271 per share
Price / Cash31.92
Book Value$2.59 per share
Price / Book2.80

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$9.13 million
Net Margins23.25%
Return on Equity21.31%
Return on Assets8.09%

Miscellaneous

Employees162
Outstanding Shares92,820,000

Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

How were Sorrento Therapeutics' earnings last quarter?

Sorrento Therapeutics (NASDAQ:SRNE) posted its quarterly earnings data on Monday, November, 16th. The biopharmaceutical company reported ($0.03) EPS for the quarter. The biopharmaceutical company earned $1.10 million during the quarter, compared to analysts' expectations of $1.28 million. Sorrento Therapeutics had a net margin of 23.25% and a return on equity of 21.31%. View Sorrento Therapeutics' Earnings History.

What price target have analysts set for SRNE?

5 brokers have issued 12-month price objectives for Sorrento Therapeutics' stock. Their forecasts range from $7.00 to $40.00. On average, they expect Sorrento Therapeutics' stock price to reach $15.75 in the next year. View Analyst Ratings for Sorrento Therapeutics.

Are investors shorting Sorrento Therapeutics?

Sorrento Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 16,542,568 shares, an increase of 9.5% from the April 13th total of 15,102,074 shares. Based on an average daily volume of 2,141,013 shares, the short-interest ratio is presently 7.7 days. Approximately 25.3% of the company's shares are sold short.

Who are some of Sorrento Therapeutics' key competitors?

Who are Sorrento Therapeutics' key executives?

Sorrento Therapeutics' management team includes the folowing people:
  • Dr. Henry H. Ji, Co-Founder, Chairman, CEO & Pres (Age 54)
  • Mr. George K. Ng, Exec. VP, Chief Admin. Officer & Chief Legal Officer (Age 44)
  • Dr. Jerome Bernard Zeldis, Chief Medical Officer and Pres of Clinical Research, Medical Affairs & Regulatory (Age 68)
  • Mr. Jiong Shao CFA, Exec. VP & CFO (Age 50)
  • Dr. Alexis Nahama, VP of Corp. Devel.

Has Sorrento Therapeutics been receiving favorable news coverage?

News articles about SRNE stock have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sorrento Therapeutics earned a media sentiment score of 0.12 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.23 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Sorrento Therapeutics' major shareholders?

Sorrento Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.40%), Millennium Management LLC (1.55%), Wells Fargo & Company MN (0.55%), UBS Group AG (0.48%), Alambic Investment Management L.P. (0.46%) and Candriam Luxembourg S.C.A. (0.34%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd, George K Ng, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde, Pacific Medtech (Bvi) Ltd Asia, Patrick Soon-Shiong and Yue Alexander Wu. View Institutional Ownership Trends for Sorrento Therapeutics.

Which major investors are buying Sorrento Therapeutics stock?

SRNE stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Wells Fargo & Company MN, UBS Group AG, Alambic Investment Management L.P., Candriam Luxembourg S.C.A., A.R.T. Advisors LLC, GSA Capital Partners LLP and Citigroup Inc.. Company insiders that have bought Sorrento Therapeutics stock in the last two years include Abg Management Ltd, George K Ng, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde and Yue Alexander Wu. View Insider Buying and Selling for Sorrento Therapeutics.

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sorrento Therapeutics' stock price today?

One share of SRNE stock can currently be purchased for approximately $7.25.

How big of a company is Sorrento Therapeutics?

Sorrento Therapeutics has a market capitalization of $668.34 million and generates $151.85 million in revenue each year. Sorrento Therapeutics employs 162 workers across the globe.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected]


MarketBeat Community Rating for Sorrento Therapeutics (SRNE)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  319 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  439
MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe SRNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRNE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sorrento Therapeutics (NASDAQ:SRNE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Sorrento Therapeutics in the last 12 months. Their average twelve-month price target is $15.75, suggesting that the stock has a possible upside of 117.24%. The high price target for SRNE is $40.00 and the low price target for SRNE is $7.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $15.75$15.3333$13.6667$11.50
Price Target Upside: 117.24% upside153.44% upside91.95% upside400.00% upside

Sorrento Therapeutics (NASDAQ:SRNE) Consensus Price Target History

Price Target History for Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics (NASDAQ:SRNE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2018HC WainwrightSet Price TargetBuy$40.00LowView Rating Details
1/19/2018OppenheimerReiterated RatingBuy$9.00HighView Rating Details
8/3/2017Roth CapitalInitiated CoverageBuy$7.00HighView Rating Details
8/3/2017UBSInitiated CoverageOutperform$7.00HighView Rating Details
6/17/2017FBR & CoReiterated RatingBuyLowView Rating Details
5/22/2017Rodman & RenshawLower Price TargetBuy ➝ Buy$30.00 ➝ $20.00HighView Rating Details
8/12/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Sorrento Therapeutics (NASDAQ:SRNE) Earnings History and Estimates Chart

Earnings by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics (NASDAQ:SRNE) Earnings Estimates

2018 EPS Consensus Estimate: ($0.58)
2019 EPS Consensus Estimate: ($0.41)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.17)($0.17)($0.17)
Q2 20181($0.16)($0.16)($0.16)
Q3 20181($0.15)($0.15)($0.15)
Q4 20181($0.10)($0.10)($0.10)
Q1 20191($0.12)($0.12)($0.12)
Q2 20191($0.10)($0.10)($0.10)
Q3 20191($0.10)($0.10)($0.10)
Q4 20191($0.09)($0.09)($0.09)

Sorrento Therapeutics (NASDAQ SRNE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017$0.44$121.91 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.20)$4.67 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.33)($0.45)$4.02 million$4.87 millionViewN/AView Earnings Details
3/21/2017Q4 2016($0.27)($0.44)$2.99 million$4.02 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.19)$2.24 millionViewN/AView Earnings Details
8/8/2016Q2 2016($0.17)($0.28)$1.11 million$0.90 millionViewN/AView Earnings Details
5/10/2016Q1 2016($0.37)($0.63)$1.34 million$0.99 millionViewN/AView Earnings Details
3/15/2016Q4 2015($0.63)$1.34 millionViewN/AView Earnings Details
11/16/2015Q315($0.03)$1.28 million$1.10 millionViewN/AView Earnings Details
8/7/2015Q2 2015($0.32)($0.30)$0.95 million$1.17 millionViewN/AView Earnings Details
5/5/2015Q1 2015($0.14)($0.29)$5.85 million$0.98 millionViewN/AView Earnings Details
3/13/2015Q4 2014($0.28)$0.80 millionViewN/AView Earnings Details
11/4/2014Q314($0.32)($0.27)$0.08 million$1.28 millionViewN/AView Earnings Details
8/6/2014($0.34)($0.33)$0.08 million$0.78 millionViewN/AView Earnings Details
5/14/2014($0.29)($0.44)$0.12 million$0.98 millionViewN/AView Earnings Details
4/1/2014Q4 2013($0.28)($0.35)$0.10 millionViewN/AView Earnings Details
11/14/2013Q3 2013($0.28)($0.23)$0.08 millionViewN/AView Earnings Details
8/13/2013Q2 2013($0.26)$0.14 millionViewN/AView Earnings Details
5/15/2013Q1 2013($0.01)$0.13 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Sorrento Therapeutics (NASDAQ:SRNE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Sorrento Therapeutics (NASDAQ SRNE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 25.01%
Insider Trading History for Sorrento Therapeutics (NASDAQ:SRNE)
Institutional Ownership by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics (NASDAQ SRNE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/28/2018George K NgInsiderBuy90,000$9.95$895,500.001,906,177View SEC Filing  
2/7/2018Abg Management LtdMajor ShareholderSell150,000$7.19$1,078,500.00View SEC Filing  
2/5/2018Abg Management LtdMajor ShareholderSell70,721$8.00$565,768.00View SEC Filing  
1/30/2018Abg Management LtdMajor ShareholderSell310,000$7.64$2,368,400.00View SEC Filing  
1/24/2018Pacific Medtech (Bvi) Ltd AsiaMajor ShareholderSell684,288$7.56$5,173,217.28View SEC Filing  
6/15/2017Henry JiInsiderBuy29,001$1.81$52,491.81139,776View SEC Filing  
6/15/2017Jaisim ShahDirectorBuy10,002$1.79$17,903.58112,633View SEC Filing  
4/19/2017Abg Management LtdMajor ShareholderBuy550,000$2.00$1,100,000.00View SEC Filing  
4/19/2017Henry JiCEOBuy100,000$2.00$200,000.00139,776View SEC Filing  
4/13/2017Abg Management LtdMajor ShareholderBuy2,500,000$2.00$5,000,000.00View SEC Filing  
2/22/2017Henry JiInsiderBuy2,000$5.60$11,200.0039,776View SEC Filing  
2/10/2017Henry JiInsiderBuy20,000$5.15$103,000.0037,776View SEC Filing  
2/3/2017Jerome B ZeldisInsiderBuy10,000$5.15$51,500.0010,000View SEC Filing  
2/3/2017Kevin HerdeVPBuy3,000$5.15$15,450.007,000View SEC Filing  
2/3/2017Yue Alexander WuDirectorBuy5,000$5.15$25,750.005,000View SEC Filing  
6/29/2016Patrick Soon-ShiongMajor ShareholderSell3,400$5.82$19,788.00720,174View SEC Filing  
6/23/2016Patrick Soon-ShiongMajor ShareholderSell6,901$5.85$40,370.85720,174View SEC Filing  
6/15/2016Patrick Soon-ShiongMajor ShareholderSell19,836$5.87$116,437.32720,174View SEC Filing  
6/14/2016Patrick Soon-ShiongMajor ShareholderSell53,764$6.14$330,110.96736,146View SEC Filing  
6/13/2016Patrick Soon-ShiongMajor ShareholderSell37,792$6.15$232,420.80736,146View SEC Filing  
3/7/2016Patrick Soon-ShiongMajor ShareholderSell100,000$6.19$619,000.00859,238View SEC Filing  
8/26/2015Henry JiCEOBuy500$0.95$475.00500View SEC Filing  
8/24/2015Henry JiCEOBuy8,888$12.84$114,121.9217,776View SEC Filing  
8/21/2015Henry JiCEOBuy8,888$13.08$116,255.0414,888View SEC Filing  
11/10/2014Henry JiCEOBuy5,999$4.83$28,975.17View SEC Filing  
11/7/2014Henry JiCEOBuy4,000$4.56$18,240.00View SEC Filing  
11/6/2014Henry JiCEOBuy3,000$4.53$13,590.00View SEC Filing  
12/5/2013Henry JiCEOBuy1,000$8.92$8,920.00View SEC Filing  
12/4/2013Henry JiCEOBuy1,000$8.54$8,540.00View SEC Filing  
11/25/2013Jaisim ShahDirectorBuy1,000$8.65$8,650.00View SEC Filing  
11/22/2013Henry JiCEOBuy1,000$8.47$8,470.00View SEC Filing  
11/22/2013Opko Health, Inc.Major ShareholderSell8,471$8.50$72,003.50View SEC Filing  
11/21/2013George UyInsiderBuy3,000$8.36$25,080.00View SEC Filing  
11/21/2013Opko Health, Inc.Major ShareholderSell4,269$8.53$36,414.57View SEC Filing  
11/20/2013Opko Health, Inc.Major ShareholderSell17,062$8.75$149,292.50View SEC Filing  
11/19/2013George UyInsiderBuy2,031$8.61$17,486.91View SEC Filing  
11/19/2013Henry JiCEOBuy2,000$8.59$17,180.00View SEC Filing  
11/19/2013Jaisim ShahDirectorBuy1,000$9.00$9,000.00View SEC Filing  
11/15/2013Opko Health, Inc.Major ShareholderSell2,710$8.75$23,712.50View SEC Filing  
11/14/2013Opko Health, Inc.Major ShareholderSell1,900$8.75$16,625.00View SEC Filing  
11/13/2013Opko Health, Inc.Major ShareholderSell13,457$8.75$117,748.75View SEC Filing  
11/8/2013Opko Health, Inc.Major ShareholderSell2,000$8.75$17,500.00View SEC Filing  
11/7/2013Opko Health, Inc.Major ShareholderSell120,380$9.03$1,087,031.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sorrento Therapeutics (NASDAQ SRNE) News Headlines

Source:
DateHeadline
Critical Contrast: Syneos Health (SYNH) and Sorrento Therapeutics (SRNE)Critical Contrast: Syneos Health (SYNH) and Sorrento Therapeutics (SRNE)
www.americanbankingnews.com - May 22 at 7:04 PM
HC Wainwright Reiterates "Buy" Rating for Sorrento Therapeutics (SRNE)HC Wainwright Reiterates "Buy" Rating for Sorrento Therapeutics (SRNE)
www.americanbankingnews.com - May 14 at 11:41 AM
Sorrento Therapeutics (SRNE) Short Interest Up 9.5% in AprilSorrento Therapeutics (SRNE) Short Interest Up 9.5% in April
www.americanbankingnews.com - May 12 at 1:06 AM
Sorrento Therapeutics (SRNE) Expected to Announce Quarterly Sales of $5.05 MillionSorrento Therapeutics (SRNE) Expected to Announce Quarterly Sales of $5.05 Million
www.americanbankingnews.com - May 9 at 5:09 AM
Sorrento Therapeutics (SRNE) Given Average Recommendation of "Buy" by BrokeragesSorrento Therapeutics (SRNE) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 5 at 1:48 AM
Sorrento Therapeutics (SRNE) Given a $40.00 Price Target at HC WainwrightSorrento Therapeutics (SRNE) Given a $40.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 4 at 10:31 PM
Cutting Our LossesCutting Our Losses
www.forbes.com - April 30 at 5:13 PM
Sorrento Therapeutics (SRNE) Upgraded to Buy by BidaskClubSorrento Therapeutics (SRNE) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - April 27 at 11:56 AM
Malvern biopharm firm developing patch-in-a-can pain relief productMalvern biopharm firm developing 'patch-in-a-can' pain relief product
www.bizjournals.com - April 27 at 8:30 AM
Sorrento Therapeutics (SRNE) China CAR-T Spin, Listing Could Dwarf US Market Cap - Evercore ISISorrento Therapeutics (SRNE) China CAR-T Spin, Listing Could Dwarf US Market Cap - Evercore ISI
www.streetinsider.com - April 27 at 8:30 AM
Sorrento Therapeutics (SRNE) Short Interest UpdateSorrento Therapeutics (SRNE) Short Interest Update
www.americanbankingnews.com - April 26 at 2:22 AM
Sorrento Therapeutics CEO Dr. Henry Ji Invited to the Fourth International Vatican Conference on “Unite to Cure”Sorrento Therapeutics CEO Dr. Henry Ji Invited to the Fourth International Vatican Conference on “Unite to Cure”
finance.yahoo.com - April 23 at 8:16 AM
Financial Comparison: Intrexon (XON) versus Sorrento Therapeutics (SRNE)Financial Comparison: Intrexon (XON) versus Sorrento Therapeutics (SRNE)
www.americanbankingnews.com - April 21 at 1:36 PM
$5.05 Million in Sales Expected for Sorrento Therapeutics (SRNE) This Quarter$5.05 Million in Sales Expected for Sorrento Therapeutics (SRNE) This Quarter
www.americanbankingnews.com - April 21 at 1:56 AM
Sorrento Therapeutics (SRNE) Given a $20.00 Price Target at HC WainwrightSorrento Therapeutics (SRNE) Given a $20.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 20 at 2:25 PM
Zacks: Brokerages Expect Sorrento Therapeutics (SRNE) Will Post Earnings of -$0.17 Per ShareZacks: Brokerages Expect Sorrento Therapeutics (SRNE) Will Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - April 19 at 11:12 PM
Cramer's lightning round: Take a long-term view on Spotif...Cramer's lightning round: Take a long-term view on Spotif...
finance.yahoo.com - April 17 at 8:32 AM
Sorrento Therapeutics (SRNE) Upgraded by TheStreet to C-Sorrento Therapeutics (SRNE) Upgraded by TheStreet to C-
www.americanbankingnews.com - April 17 at 8:17 AM
Financial Contrast: Luna Innovations (LUNA) & Sorrento Therapeutics (SRNE)Financial Contrast: Luna Innovations (LUNA) & Sorrento Therapeutics (SRNE)
www.americanbankingnews.com - April 13 at 1:30 PM
Sorrento Therapeutics (SRNE) Given a $40.00 Price Target by HC Wainwright AnalystsSorrento Therapeutics (SRNE) Given a $40.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 12 at 11:17 AM
Short Interest in Sorrento Therapeutics Inc (SRNE) Increases By 45.4%Short Interest in Sorrento Therapeutics Inc (SRNE) Increases By 45.4%
www.americanbankingnews.com - April 12 at 1:09 AM
Sorrento Therapeutics (SRNE) Given a $7.00 Price Target at OppenheimerSorrento Therapeutics (SRNE) Given a $7.00 Price Target at Oppenheimer
www.americanbankingnews.com - April 10 at 8:23 PM
Sorrento Therapeutics Inc (SRNE) Receives Average Recommendation of "Buy" from BrokeragesSorrento Therapeutics Inc (SRNE) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 10 at 1:41 AM
Sorrento Therapeutics (SRNE) PT Set at $7.00 by OppenheimerSorrento Therapeutics (SRNE) PT Set at $7.00 by Oppenheimer
www.americanbankingnews.com - April 9 at 11:59 PM
Form 8-K Sorrento Therapeutics, For: Apr 05Form 8-K Sorrento Therapeutics, For: Apr 05
www.streetinsider.com - April 5 at 5:17 PM
Sorrento Therapeutics (SRNE), Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With R/R Multiple ...Sorrento Therapeutics (SRNE), Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With R/R Multiple ...
www.streetinsider.com - April 5 at 5:17 PM
Sorrento Therapeutics to Present at HC Wainwright Global Lifesciences Conference 04/09/18Sorrento Therapeutics to Present at HC Wainwright Global Lifesciences Conference 04/09/18
globenewswire.com - April 5 at 5:17 PM
Sorrento and Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With Relapsed or Refractory Multiple Myeloma (NCT03464916)Sorrento and Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With Relapsed or Refractory Multiple Myeloma (NCT03464916)
finance.yahoo.com - April 5 at 5:17 PM
Sorrento Therapeutics (SRNE) Upgraded at ValuEngineSorrento Therapeutics (SRNE) Upgraded at ValuEngine
www.americanbankingnews.com - April 5 at 2:08 PM
Sorrento Therapeutics to Present at H.C. Wainwright Global Lifesciences Conference 04/09/18Sorrento Therapeutics to Present at H.C. Wainwright Global Lifesciences Conference 04/09/18
finance.yahoo.com - April 5 at 10:12 AM
Sorrento Therapeutics Inc (SRNE) Expected to Announce Quarterly Sales of $4.50 MillionSorrento Therapeutics Inc (SRNE) Expected to Announce Quarterly Sales of $4.50 Million
www.americanbankingnews.com - April 5 at 5:56 AM
HC Wainwright Reiterates Buy Rating for Sorrento Therapeutics (SRNE)HC Wainwright Reiterates Buy Rating for Sorrento Therapeutics (SRNE)
www.americanbankingnews.com - April 3 at 7:49 AM
Sorrento Therapeutics (SRNE) & Medpace (MEDP) Head to Head ContrastSorrento Therapeutics (SRNE) & Medpace (MEDP) Head to Head Contrast
www.americanbankingnews.com - April 3 at 5:17 AM
Zacks: Analysts Anticipate Sorrento Therapeutics Inc (SRNE) Will Announce Earnings of -$0.14 Per ShareZacks: Analysts Anticipate Sorrento Therapeutics Inc (SRNE) Will Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - April 3 at 1:16 AM
Sorrento Therapeutics (SRNE) Stock Rating Upgraded by ValuEngineSorrento Therapeutics (SRNE) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 31 at 12:42 PM
Sorrento lists key milestones for 2018Sorrento lists key milestones for 2018
seekingalpha.com - March 31 at 8:19 AM
Why the Sudden Surge in Sorrento Therapeutics’ Revenue?Why the Sudden Surge in Sorrento Therapeutics’ Revenue?
finance.yahoo.com - March 29 at 5:29 PM
Sorrento Therapeutics (SRNE) Downgraded by BidaskClubSorrento Therapeutics (SRNE) Downgraded by BidaskClub
www.americanbankingnews.com - March 29 at 9:15 AM
Your Daily Pharma Scoop: Sorrento Sell-Off, Bluebird/Celgene Agreement, Edge Therapeutics SetbackYour Daily Pharma Scoop: Sorrento Sell-Off, Bluebird/Celgene Agreement, Edge Therapeutics' Setback
seekingalpha.com - March 29 at 8:29 AM
Sorrento Therapeutics Chairman/CEO update to stockholdersSorrento Therapeutics Chairman/CEO update to stockholders
finance.yahoo.com - March 29 at 8:29 AM
Why Sorrento Therapeutics Inc. Is Getting Beaten Down TodayWhy Sorrento Therapeutics Inc. Is Getting Beaten Down Today
finance.yahoo.com - March 28 at 5:17 PM
Sorrento Therapeutics Inc (SRNE) Sees Significant Increase in Short InterestSorrento Therapeutics Inc (SRNE) Sees Significant Increase in Short Interest
www.americanbankingnews.com - March 28 at 2:02 AM
Sorrento down 8% on convertible debt deal, cautious SA articleSorrento down 8% on convertible debt deal, cautious SA article
seekingalpha.com - March 27 at 5:13 PM
Sorrento Therapeutics Announces Unsecured $120.5M Convertible Note FinancingSorrento Therapeutics Announces Unsecured $120.5M Convertible Note Financing
finance.yahoo.com - March 27 at 8:29 AM
BidaskClub Downgrades Sorrento Therapeutics (SRNE) to BuyBidaskClub Downgrades Sorrento Therapeutics (SRNE) to Buy
www.americanbankingnews.com - March 24 at 12:28 PM
Oppenheimer Comments on Sorrento Therapeutics Incs Q1 2018 Earnings (SRNE)Oppenheimer Comments on Sorrento Therapeutics Inc's Q1 2018 Earnings (SRNE)
www.americanbankingnews.com - March 22 at 8:12 AM
Oppenheimer Research Analysts Raise Earnings Estimates for Sorrento Therapeutics Inc (SRNE)Oppenheimer Research Analysts Raise Earnings Estimates for Sorrento Therapeutics Inc (SRNE)
www.americanbankingnews.com - March 21 at 4:02 PM
Sorrento Therapeutics CEO Dr Ji to Present at Needham 17th Annual Healthcare Conference on 03/27/18 - GlobeNewswire (press release)Sorrento Therapeutics CEO Dr Ji to Present at Needham 17th Annual Healthcare Conference on 03/27/18 - GlobeNewswire (press release)
globenewswire.com - March 21 at 8:55 AM
Sorrento Therapeutics (SRNE) Names Jiong Shao as CFO; Reaffirms Intent to Seek Nasdaq/HKSE Dual Listing in 2018 - StreetInsider.comSorrento Therapeutics (SRNE) Names Jiong Shao as CFO; Reaffirms Intent to Seek Nasdaq/HKSE Dual Listing in 2018 - StreetInsider.com
www.streetinsider.com - March 19 at 8:24 AM
Sorrento Therapeutics Welcomes Jiong Shao as Chief Financial Officer and Reaffirms Intent to Seek Nasdaq/HKSE Dual Listing in 2018Sorrento Therapeutics Welcomes Jiong Shao as Chief Financial Officer and Reaffirms Intent to Seek Nasdaq/HKSE Dual Listing in 2018
finance.yahoo.com - March 19 at 8:23 AM

SEC Filings

Sorrento Therapeutics (NASDAQ:SRNE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sorrento Therapeutics (NASDAQ:SRNE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sorrento Therapeutics (NASDAQ SRNE) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.